PT1865961E - Famciclovir para o tratamento do herpes labial recorrente utilizando um tratamento de um dia - Google Patents
Famciclovir para o tratamento do herpes labial recorrente utilizando um tratamento de um dia Download PDFInfo
- Publication number
- PT1865961E PT1865961E PT06739956T PT06739956T PT1865961E PT 1865961 E PT1865961 E PT 1865961E PT 06739956 T PT06739956 T PT 06739956T PT 06739956 T PT06739956 T PT 06739956T PT 1865961 E PT1865961 E PT 1865961E
- Authority
- PT
- Portugal
- Prior art keywords
- compound
- day
- treatment
- lesions
- use according
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 66
- 208000004898 Herpes Labialis Diseases 0.000 title claims abstract description 39
- 206010067152 Oral herpes Diseases 0.000 title claims abstract description 33
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960004396 famciclovir Drugs 0.000 title claims abstract description 29
- 230000000306 recurrent effect Effects 0.000 title claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 45
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 11
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 abstract description 10
- 229960001179 penciclovir Drugs 0.000 abstract description 10
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000003902 lesion Effects 0.000 description 94
- 230000035876 healing Effects 0.000 description 45
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- 239000003814 drug Substances 0.000 description 20
- 206010039509 Scab Diseases 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 208000025865 Ulcer Diseases 0.000 description 12
- 231100000397 ulcer Toxicity 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940104320 famciclovir 750 mg Drugs 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000037048 Prodromal Symptoms Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- -1 phosphate ester Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940093257 valacyclovir Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940097919 famciclovir 500 mg Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66653605P | 2005-03-30 | 2005-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1865961E true PT1865961E (pt) | 2012-05-22 |
Family
ID=36829888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06739956T PT1865961E (pt) | 2005-03-30 | 2006-03-29 | Famciclovir para o tratamento do herpes labial recorrente utilizando um tratamento de um dia |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20100298353A1 (enExample) |
| EP (2) | EP2363131A1 (enExample) |
| JP (3) | JP2008534603A (enExample) |
| KR (1) | KR101312820B1 (enExample) |
| CN (1) | CN101678028A (enExample) |
| AT (1) | ATE545419T1 (enExample) |
| AU (3) | AU2006230269A1 (enExample) |
| BR (1) | BRPI0609793A2 (enExample) |
| CA (1) | CA2602641A1 (enExample) |
| ES (1) | ES2382664T3 (enExample) |
| PL (1) | PL1865961T3 (enExample) |
| PT (1) | PT1865961E (enExample) |
| RU (2) | RU2007139762A (enExample) |
| TW (1) | TW200716124A (enExample) |
| WO (1) | WO2006105194A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006230269A1 (en) * | 2005-03-30 | 2006-10-05 | Novartis Ag | Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485225D1 (de) | 1983-08-18 | 1991-12-05 | Beecham Group Plc | Antivirale guanin-derivate. |
| DE3582399D1 (de) | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
| DE3671227D1 (de) | 1985-07-27 | 1990-06-21 | Beecham Group Plc | 9-substituierte guaninmonohydrate. |
| GB8628826D0 (en) | 1986-12-02 | 1987-01-07 | Beecham Group Plc | Pharmaceutical products |
| US5840763A (en) * | 1994-12-12 | 1998-11-24 | Smithkline Beecham Plc | Treatment of a latent infection of herpes viruses |
| RU2179849C2 (ru) * | 1999-07-27 | 2002-02-27 | Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии | Способ лечения рецидивирующего генитального герпеса у женщин |
| RU2178699C1 (ru) * | 2001-04-04 | 2002-01-27 | Змызгова Анна Васильевна | Способ лечения герпесовирусных инфекций, включающий озонотерапию |
| AU2006230269A1 (en) * | 2005-03-30 | 2006-10-05 | Novartis Ag | Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application |
-
2006
- 2006-03-28 AU AU2006230269A patent/AU2006230269A1/en not_active Abandoned
- 2006-03-29 EP EP10179668A patent/EP2363131A1/en not_active Withdrawn
- 2006-03-29 EP EP06739956A patent/EP1865961B1/en active Active
- 2006-03-29 RU RU2007139762/14A patent/RU2007139762A/ru unknown
- 2006-03-29 PL PL06739956T patent/PL1865961T3/pl unknown
- 2006-03-29 KR KR1020077024918A patent/KR101312820B1/ko not_active Expired - Fee Related
- 2006-03-29 ES ES06739956T patent/ES2382664T3/es active Active
- 2006-03-29 WO PCT/US2006/011460 patent/WO2006105194A2/en not_active Ceased
- 2006-03-29 JP JP2008504316A patent/JP2008534603A/ja not_active Withdrawn
- 2006-03-29 PT PT06739956T patent/PT1865961E/pt unknown
- 2006-03-29 TW TW095110943A patent/TW200716124A/zh unknown
- 2006-03-29 RU RU2007139758/15A patent/RU2432951C2/ru active
- 2006-03-29 CA CA002602641A patent/CA2602641A1/en not_active Abandoned
- 2006-03-29 AT AT06739956T patent/ATE545419T1/de active
- 2006-03-29 AU AU2006230291A patent/AU2006230291A1/en not_active Abandoned
- 2006-03-29 BR BRPI0609793-6A patent/BRPI0609793A2/pt not_active IP Right Cessation
- 2006-03-29 CN CN200680010840A patent/CN101678028A/zh active Pending
-
2010
- 2010-05-06 AU AU2010201834A patent/AU2010201834B2/en not_active Expired - Fee Related
- 2010-07-01 US US12/803,649 patent/US20100298353A1/en not_active Abandoned
-
2011
- 2011-12-20 US US13/330,979 patent/US20120088781A1/en not_active Abandoned
-
2012
- 2012-09-06 US US13/604,955 patent/US20120329814A1/en not_active Abandoned
- 2012-10-19 JP JP2012232172A patent/JP6018473B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-14 US US14/252,514 patent/US20150005324A1/en not_active Abandoned
-
2015
- 2015-04-01 JP JP2015075416A patent/JP2015163614A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010201834A1 (en) | 2010-05-27 |
| US20100298353A1 (en) | 2010-11-25 |
| US20120329814A1 (en) | 2012-12-27 |
| JP2013049687A (ja) | 2013-03-14 |
| KR101312820B1 (ko) | 2013-09-27 |
| KR20080004535A (ko) | 2008-01-09 |
| JP2008534603A (ja) | 2008-08-28 |
| ATE545419T1 (de) | 2012-03-15 |
| RU2007139762A (ru) | 2009-05-10 |
| AU2006230291A8 (en) | 2013-10-24 |
| PL1865961T3 (pl) | 2012-07-31 |
| WO2006105194A2 (en) | 2006-10-05 |
| EP2363131A1 (en) | 2011-09-07 |
| EP1865961B1 (en) | 2012-02-15 |
| RU2007139758A (ru) | 2009-05-10 |
| WO2006105194A3 (en) | 2006-12-21 |
| RU2432951C2 (ru) | 2011-11-10 |
| BRPI0609793A2 (pt) | 2010-04-27 |
| JP2015163614A (ja) | 2015-09-10 |
| AU2006230269A1 (en) | 2006-10-05 |
| US20150005324A1 (en) | 2015-01-01 |
| AU2006230291A1 (en) | 2006-10-05 |
| TW200716124A (en) | 2007-05-01 |
| CA2602641A1 (en) | 2006-10-05 |
| ES2382664T3 (es) | 2012-06-12 |
| JP6018473B2 (ja) | 2016-11-02 |
| CN101678028A (zh) | 2010-03-24 |
| US20120088781A1 (en) | 2012-04-12 |
| AU2010201834B2 (en) | 2012-04-19 |
| EP1865961A1 (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2685814T3 (es) | Procedimientos de tratamiento de pacientes pediátricos usando dexmedetomidina | |
| Dallos et al. | Use of amantadine in Parkinson's disease. Results of a double-blind trial | |
| CN112773765A (zh) | 治疗普拉德-威利综合征的方法 | |
| Nemati et al. | Clinical study of ticrynafen: A new diuretic, antihypertensive, and uricosuric agent | |
| Levy et al. | The effect of dosage form upon the gastrointestinal absorption rate of salicylates | |
| PT1865961E (pt) | Famciclovir para o tratamento do herpes labial recorrente utilizando um tratamento de um dia | |
| Mitchell | Herpes gestationis and the “pill” | |
| Burton | Rash and pulmonary eosinophilia associated with fenbufen | |
| AU2010201836B2 (en) | Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment | |
| Chudry et al. | Nedocromil sodium and exercise induced asthma. | |
| US10272039B2 (en) | Topical sodium nitrite formulation | |
| US20120329815A1 (en) | Famciclovir for the Treatment of Recurrent Herpes Labialis using a One-Day Treatment | |
| Williams | Multi-centre clinical trial of nedocromil sodium in reversible obstructive airways disease in adults: a general practitioner collaborative study | |
| CAWOOD | DONALD J. DALESSIO. | |
| Marshall | TAKE A DEEP BREATH... | |
| Size | Other New Products | |
| Rajamannan | Próximo pago de haberes | |
| KR20080004536A (ko) | 1-일 적용으로 재발성 음부 헤르페스를 치료하기 위한펜시클로버 또는 팜시클로버 |